Progression in diagnostic technologies is driving market growth.
New York, USA, Dec. 04, 2024 (GLOBE NEWSWIRE) — Market Overview:
The global tumor-induced osteomalacia market size was USD 118.25 million in 2024, estimated at USD 121.12 million in 2025, and is expected to reach around USD 153.00 million by 2034, expanding at a CAGR of 2.6% from 2025 to 2034.
What is Tumor-Induced Osteomalacia?
Tumor-induced osteomalacia is an infrequent paraneoplastic illness generated by tumors that discharge fibroblast growth factor 23. Due to the role of FGF23, renal phosphate management, and vitamin D synthesis, TIO is portrayed by reduced renal tubular reabsorption of phosphate by hypophosphatemia and by the reduced degree of agile vitamin D. Detrimental hypophosphatemia finally causes osteomalacia. The detection of TIO is usually reckoned when serum phosphate degrees are perpetually low in establishing bone pain, frailty fractures, and muscle weakness.
Download Free Sample PDF Copy of the Report:
Key Takeaways from the Report:
- The market is expected to exhibit a CAGR of 2.6%.
- The market for tumor-induced osteomalacia is expanding due to growing consciousness about scarce bone illnesses.
- The tumor-induced osteomalacia market analysis is primarily based on treatment type, end users, and region.
- Based on treatment type, the drugs & supplements segment dominated the market.
- North America dominated the market with the largest share and is anticipated to continue its dominance during the forecast period.
Tumor-Induced Osteomalacia Market Dynamics:
Growth Drivers:
- Growing Cases of Targeted Therapies: The tumor-induced osteomalacia market size is expanding due to the growing concentration on earmarked therapies. With progression in molecular biology, researchers have advanced therapies that particularly target the cardinal causes of TIO especially by hampering the fibroblast growth factor-23 (FGF23) accountable for phosphate loss. Clinical trials, including FGF23 inhibitors such as burosumab, have displayed encouraging outcomes in curing patients from developing TIO, enhancing phosphate levels, and decreasing bone pain.
- Awareness about Rare Illnesses: Consciousness adjoining scarce illnesses involving tumor-induced osteomalacia has notably escalated over the last decade. The surge in the consciousness has caused more punctual and precise diagnosis of the condition which is important for premature cure and prohibition of critical hurdles. Worldwide directives such as Rare Disease Day and the setting of patient approval categories have played an important part in instructing both healthcare experts and people about the signs and symptoms of TIO.
Request for a Discount on this Report Before Purchase:
Trends and Opportunities:
- Growing Research and Development: The advancement of contemporary therapies such as fibroblast growth factor-23 inhibitors and growing research and development ventures for superlative cure alternatives are anticipated to be prominent trends in the market. Associations between pharmaceutical firms and research organizations targeted at confronting discontented clinical requirements suggest that tumor-induced osteomalacia market demand is expanding.
- Progression in Diagnostic Technologies: Progression in diagnostic technologies is also driving the market forward. With the growing usage of next-generation sequencing and positron emission tomography (PET) scans, healthcare experts can more precisely locate the tumors causing osteomalacia.
Competitive Analysis:
The firms are tied up in advancing therapies targeted at inscribing the fundamental motifs of TIO, such as fibroblast growth factor-23 (FGF23) venture or handling phosphate degrees in patients. The firms are concentrated on additional clinical research to augment the indicators for this cure while also partnering with research firms to improve treatment agreements.
Major players operating in tumor-induced osteomalacia market:
- Ultragenyx Pharmaceutical Inc.
- Kyowa Kirin Co., Ltd.
- Eli Lilly and Company
- Amgen Inc.
- Novartis AG
- Sanofi S.A.
- Pfizer Inc.
- AbbVie Inc.
- Horizon Therapeutics
Regional Insights:
- North America: The market held the largest share due to the elevated degree of consciousness, progressive healthcare framework, and the existence of spearheading pharmaceutical firms included in the advancement of earmarked therapies such as FGF23 inhibitors. The obtainability of progressive diagnostic technologies, together with robust funding in research and development, drives the market in North America.
- Europe: Growing consciousness and progressions in scarce disease handling and a robust healthcare system are expected to drive Europe’s tumor-induced osteomalacia market with the highest CAGR during the forecast period.
Inquire more about this report before purchase:
Europe Tumor-Induced Osteomalacia Market Segmentation:
By Treatment Type Outlook:
- Drugs & Supplements
- Surgery
By End Users Outlook:
- Hospitals
- Ambulatory Surgery Centers
- Specialty Clinics
- Others
By Region Outlook:
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of the Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
More Trending Latest Reports by Polaris Market Research:
About Polaris Market Research & Consulting, Inc:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR’s clientele spread across different enterprises. We at Polaris are obliged to serve PMR’s diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR’s customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR’s customers.
Contact:
Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
Follow Us: LinkedIn | Twitter
- Golden Triangle Ventures Restructures Over $7M in Legacy Debt, Secures Strategic Investor to Strengthen Capital Table and Accelerate Growth - July 1, 2025
- SIMPPLE Ltd. Announces Results of AGM - July 1, 2025
- Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio - July 1, 2025
